The findings revealed no discernible disparity in intracellular ROS levels between NLRP4-knockdown pancreatic cancer cells and control cells treated with MitoQ (Fig. 7a, b and Extended Data Fig. 7a, b). Here, NLRP4 is linked to familial pancreatic carcinoma.